Updated

Analysts raised their price targets on Eli Lilly, projecting roughly 20% upside for the pharmaceutical giant's shares. The revision reflects continued optimism about the company's growth trajectory, particularly in its weight-loss and metabolic drug franchises. The upgrade adds to a string of bullish analyst commentary on Eli Lilly this year as the company continues to benefit from strong demand for its GLP-1 drugs.